Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 | P23921 | 18/20 | 0.36 |
| ▸ | RRM2B | Q7LG56 | 18/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 17/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 17/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948192 | 1.00 | RRM1 (0.36) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL23529337 | 0.93 | PTGER4 (0.33) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL29948206 | 0.93 | PTGER4 (0.33) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL29948137 | 0.89 | NOTUM (0.40) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL23529308 | 0.89 | NOTUM (0.40) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL24801625 | 0.88 | NOTUM (0.44) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL29948143 | 0.88 | NOTUM (0.44) | RRM1RRM2BCHRM2CHRM1NOTUM | |
| SCHEMBL23552398 | 0.84 | PTGER4 (0.41) | — | |
| SCHEMBL29948164 | 0.84 | PTGER4 (0.41) | — | |
| SCHEMBL23529396 | 0.82 | GPR35 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | claimed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | claimed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | claimed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | claimed |
| CN-114981265-A | Compound (I) | CTXT私人有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| CN-114981265-A | Compound (I) | CTXT私人有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | RRM1 2741/4885RRM2B 1464/4885CHRM2 2790/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | RRM1 843/4885RRM2B 461/4885CHRM2 161/4885 |
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | RRM1 3047/4885RRM2B 1605/4885CHRM2 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.